[go: up one dir, main page]

UY32709A - Composiciones farmacéuticas acuosas que contienen complejos borato-poliol - Google Patents

Composiciones farmacéuticas acuosas que contienen complejos borato-poliol

Info

Publication number
UY32709A
UY32709A UY0001032709A UY32709A UY32709A UY 32709 A UY32709 A UY 32709A UY 0001032709 A UY0001032709 A UY 0001032709A UY 32709 A UY32709 A UY 32709A UY 32709 A UY32709 A UY 32709A
Authority
UY
Uruguay
Prior art keywords
pharmaceutical
borato
compositions containing
polyol complexes
pharmaceutical compositions
Prior art date
Application number
UY0001032709A
Other languages
English (en)
Inventor
Bragwati P Kabra
Original Assignee
Alcon Res Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42364357&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UY32709(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Alcon Res Ltd filed Critical Alcon Res Ltd
Publication of UY32709A publication Critical patent/UY32709A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/186—Quaternary ammonium compounds, e.g. benzalkonium chloride or cetrimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invención está dirigida a suministrar composiciones oftálmicas de dosis múltiples. Estas composiciones poseen suficiente actividad antimicrobiana para satisfacer los requisitos de eficacia de las normas USP para conservantes, así como normas similares sobre conservantes (por ejemplo, EP y JP). Las composiciones incluyen dos polioles diferente conjuntamente con borato y una concentración baja de cloruro de benzalconio.
UY0001032709A 2009-06-19 2010-06-14 Composiciones farmacéuticas acuosas que contienen complejos borato-poliol UY32709A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US21847209P 2009-06-19 2009-06-19

Publications (1)

Publication Number Publication Date
UY32709A true UY32709A (es) 2010-12-31

Family

ID=42364357

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001032709A UY32709A (es) 2009-06-19 2010-06-14 Composiciones farmacéuticas acuosas que contienen complejos borato-poliol

Country Status (26)

Country Link
US (3) US9044484B2 (es)
EP (4) EP3437634A1 (es)
JP (3) JP6017956B2 (es)
KR (1) KR101738502B1 (es)
CN (2) CN104707145A (es)
AR (2) AR077126A1 (es)
AU (1) AU2010262898B2 (es)
BR (1) BRPI1015996B8 (es)
CA (1) CA2763778C (es)
CL (1) CL2010000634A1 (es)
CY (2) CY1117835T1 (es)
DK (3) DK3045164T3 (es)
ES (3) ES2584858T3 (es)
HR (2) HRP20160953T1 (es)
HU (2) HUE030435T2 (es)
LT (1) LT3045164T (es)
MX (1) MX2011013107A (es)
PL (3) PL2722035T3 (es)
PT (3) PT2442790E (es)
RU (1) RU2563125C2 (es)
SI (3) SI2442790T1 (es)
SM (1) SMT201600249B (es)
TW (1) TWI489997B (es)
UY (1) UY32709A (es)
WO (1) WO2010148190A1 (es)
ZA (1) ZA201108384B (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101541303B1 (ko) * 2008-03-17 2015-08-03 알콘 리서치, 리미티드 보레이트-폴리올 복합체를 함유하는 수성 약학적 조성물
TWI489997B (zh) 2009-06-19 2015-07-01 Alcon Res Ltd 含有硼酸－多元醇錯合物之水性藥學組成物
BR112013018025A2 (pt) 2011-01-18 2020-10-27 Senju Pharmaceutical Co., Ltd composição de bromfenac líquida aquosa método para reforçar a eficácia conservante de uma solução aquosa
KR20140022901A (ko) 2011-04-22 2014-02-25 알콘 리서치, 리미티드 2종의 상이한 점도 증강제를 포함하는 점도 증강 시스템을 갖는 안과 조성물
CN104039307A (zh) 2011-04-22 2014-09-10 爱尔康研究有限公司 具有包含两种不同粘度增强剂的粘度增强体系的眼用组合物
US20120312840A1 (en) * 2011-05-13 2012-12-13 Ayako Hasegawa Container closure system with integral antimicrobial additives
TWI544922B (zh) 2011-05-19 2016-08-11 愛爾康研究有限公司 高濃度歐羅派特錠（ｏｌｏｐａｔａｄｉｎｅ）眼用組成物
ES2835398T3 (es) 2013-02-01 2021-06-22 Ocuphire Pharma Inc Métodos y composiciones para la administración oftálmica diaria de fentolamina para mejorar el rendimiento visual
CA2899339C (en) 2013-02-01 2021-07-06 Ocularis Pharma, Llc Aqueous ophthalmic solutions of phentolamine and medical uses thereof
US9693563B2 (en) 2013-08-20 2017-07-04 3M Innovative Properties Company Boron-silane polyether complex
WO2017217450A1 (ja) * 2016-06-15 2017-12-21 千寿製薬株式会社 眼科用医薬製品
JP6247430B1 (ja) * 2016-06-15 2017-12-13 千寿製薬株式会社 眼科用医薬製品
CN106237337B (zh) * 2016-08-05 2019-11-08 河南中帅医药科技股份有限公司 一种液体药物制剂用防腐组合物
GR1009419B (el) * 2017-11-07 2018-12-14 Φαρματεν Αβεε Οφθαλμικο φαρμακευτικο σκευασμα που περιεχει εναν συνδυασμο βρινζολαμιδης και βριμονιδινης και μεθοδος για την παρασκευη αυτου
JP7413040B2 (ja) 2018-02-21 2024-01-15 三菱重工サーマルシステムズ株式会社 スクロール流体機械及びその設計方法
JP2022508715A (ja) 2018-10-15 2022-01-19 オキュフィア・ファーマ・インコーポレイテッド 緑内障および関連状態の処置のための方法および組成物
MX2021004708A (es) 2018-10-26 2021-11-03 Ocuphire Pharma Inc Metodos y composiciones para tratamiento de presbicia, midriasis y otros trastornos oculares.
HRP20220165T1 (hr) 2019-07-23 2022-04-29 Nicox Ophthalmics, Inc. Postupak priprave sterilnih oftalmoloških vodenih suspenzija nanokristala flurikazona-propionata oblika a
WO2021220194A1 (en) 2020-04-29 2021-11-04 Sentiss Pharma Private Limited Ophthalmic compositions comprising a combination of brinzolamide and brimonidine
US11850249B2 (en) 2020-10-05 2023-12-26 Somerset Therapeutics, Llc Methods of efficiently reducing intraocular pressure
CN115368310B (zh) 2021-05-18 2025-06-27 奥库菲尔医药公司 合成甲磺酸酚妥拉明的方法
WO2025174723A1 (en) * 2024-02-12 2025-08-21 Selagine Inc. Ophthalmic composition comprising cethromycin

Family Cites Families (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3931319A (en) 1974-10-29 1976-01-06 Millmaster Onyx Corporation Capped polymers
US4027020A (en) 1974-10-29 1977-05-31 Millmaster Onyx Corporation Randomly terminated capped polymers
GB2084870B (en) 1980-10-10 1985-05-09 Muhlemann R Hans Oral compositions containing pyrimidine amine compounds and zinc salts
US4525346A (en) 1981-09-28 1985-06-25 Alcon Laboratories, Inc. Aqueous antimicrobial ophthalmic solutions
US4407791A (en) 1981-09-28 1983-10-04 Alcon Laboratories, Inc. Ophthalmic solutions
US4836986A (en) 1984-09-28 1989-06-06 Bausch & Lomb Incorporated Disinfecting and preserving systems and methods of use
US5607698A (en) 1988-08-04 1997-03-04 Ciba-Geigy Corporation Method of preserving ophthalmic solution and compositions therefor
US5037647A (en) 1988-09-15 1991-08-06 Alcon Laboratories, Inc. Aqueous antimicrobial opthalmic solutions comprised of quaternary ammonium compound, citric acid, citrate and sodium chloride
CA2003198C (en) 1988-11-29 1995-03-21 Anthony J. Dziabo, Jr. Aqueous ophthalmic solutions and method for preserving same
US5130298A (en) 1989-05-16 1992-07-14 Ethicon, Inc. Stabilized compositions containing epidermal growth factor
US5145643A (en) 1990-01-05 1992-09-08 Allergan, Inc. Nonoxidative ophthalmic compositions and methods for preserving and using same
US5221664A (en) 1990-04-23 1993-06-22 Magainin Pharmaaceuticals Inc. Composition and treatment with biologically active peptides and toxic cations
JP3058656B2 (ja) 1990-06-18 2000-07-04 トーメー産業株式会社 コンタクトレンズ用液剤組成物及びそれを用いたコンタクトレンズの洗浄若しくは保存方法
AU653768B2 (en) 1990-12-27 1994-10-13 Advanced Medical Optics, Inc. Method and composition for disinfecting contact lenses
US5460834A (en) 1991-12-13 1995-10-24 Alcon Laboratories, Inc. Combinations of polymers for use in physiological tear compositions
JP2873530B2 (ja) * 1991-12-13 1999-03-24 参天製薬株式会社 ニュートン型粘性を示すカルボキシビニルポリマー含有点眼液基剤
US5505953A (en) 1992-05-06 1996-04-09 Alcon Laboratories, Inc. Use of borate-polyol complexes in ophthalmic compositions
DE69333850T3 (de) 1992-05-06 2011-03-17 Alcon Laboratories, Inc., Fort Worth Anwendung von boral-polyol-komplexen für ophthalmische arzneizusammensetzungen
US5352708A (en) 1992-09-21 1994-10-04 Allergan, Inc. Non-acidic cyclopentane heptanoic acid, 2-cycloalkyl or arylalkyl derivatives as therapeutic agents
US5300287A (en) 1992-11-04 1994-04-05 Alcon Laboratories, Inc. Polymeric antimicrobials and their use in pharmaceutical compositions
US5320843A (en) 1992-12-10 1994-06-14 Polymer Technology Corporation Method for improving antibacterial properties of ophthalmic solutions
CA2088927A1 (en) * 1993-02-11 1994-08-12 Donald Skeffington Preservative system for vitamin e aqueous solution
US5736165A (en) 1993-05-25 1998-04-07 Allergan In-the-eye use of chlorine dioxide-containing compositions
TW274516B (es) 1993-11-12 1996-04-21 Ciba Geigy Ag
WO1996003158A1 (en) 1994-07-22 1996-02-08 Alcon Laboratories, Inc. Use of low molecular weight amino acids in ophthalmic compositions
US5603929A (en) 1994-11-16 1997-02-18 Alcon Laboratories, Inc. Preserved ophthalmic drug compositions containing polymeric quaternary ammonium compounds
US6024954A (en) 1994-12-12 2000-02-15 Allergan Compositions and methods for disinfecting contact lenses and preserving contact lens care products
US6011062A (en) 1994-12-22 2000-01-04 Alcon Laboratories, Inc. Storage-stable prostaglandin compositions
US5631287A (en) 1994-12-22 1997-05-20 Alcon Laboratories, Inc. Storage-stable prostaglandin compositions
CA2211361A1 (en) 1995-03-20 1996-09-26 Unilever Plc Liquid cleansing formulations
US5683993A (en) 1995-06-22 1997-11-04 Ciba Vision Corporation Compositions and methods for stabilizing polymers
HU225329B1 (en) 1996-09-12 2006-09-28 Richter Gedeon Vegyeszet Use of zinc or cobalt hyaluronate associate for the manufacture of pharmaceutical compositions of antimicrobial activity
US6121315A (en) 1996-09-20 2000-09-19 Warner-Lambert Company Oral compositions containing a zinc compound
US5820822A (en) 1996-10-25 1998-10-13 Kross; Robert D. Antimicrobial composition and method of use
JPH10130156A (ja) 1996-10-30 1998-05-19 Teika Seiyaku Kk 点眼剤組成物
US6071904A (en) 1996-12-11 2000-06-06 Alcon Laboratories, Inc. Process for manufacturing ophthalmic suspensions
PT1190718E (pt) 1996-12-13 2006-08-31 Alcon Lab Inc Composicoes oftalmicas contendo aminoalcoois
US5858346A (en) 1997-05-09 1999-01-12 Allergan Compositions and methods for enhancing contact lens wearability
US6265444B1 (en) 1997-05-23 2001-07-24 Insite Vision Incorporated Ophthalmic composition
DE69839355T2 (de) 1997-07-29 2009-06-04 Alcon Laboratories, Inc., Fort Worth Ophthalmische Zusammensetzungen enthaltend Galaktomannanpolymere und Borat
WO2004073708A1 (en) * 1998-12-17 2004-09-02 Dean Thomas R Brinzolamide and brimonidine for treating ocular conditions
US6034043A (en) 1999-04-20 2000-03-07 Lever Brothers Company, Division Of Conopco, Inc. Mild antimicrobial liquid cleansing formulations comprising polyvalent cation or cations for improving an antimicrobial effectiveness
US6482799B1 (en) 1999-05-25 2002-11-19 The Regents Of The University Of California Self-preserving multipurpose ophthalmic solutions incorporating a polypeptide antimicrobial
US6166012A (en) 1999-07-30 2000-12-26 Allergan Sales, Inc. Antibiotic compositions and method for using same
CN1477929A (zh) 2000-11-29 2004-02-25 ��˹��ŵ�� 水性消毒系统
AR035509A1 (es) 2000-12-21 2004-06-02 Alcon Inc Solucion de lagrimas artificiales mejorada que contiene una combinacion de tres emolientes y el uso de dicha solucion para la fabricacion de un medicamento
JP4844706B2 (ja) 2001-03-12 2011-12-28 ライオン株式会社 眼科用組成物
US6743439B1 (en) * 2001-06-27 2004-06-01 Alcon, Inc. Ophthalmic compositions containing copolymers of sulfonated styrene and maleic anhydride
JP4863589B2 (ja) 2001-09-28 2012-01-25 ロート製薬株式会社 水性組成物
US7074827B2 (en) 2002-10-24 2006-07-11 Sucampo Ag (Usa) Inc. Method for treating ocular hypertension and glaucoma
TWI322828B (en) 2002-12-23 2010-04-01 Alcon Inc Use of multifunctional surface active agents to clean contact lenses
CN100341498C (zh) * 2003-01-21 2007-10-10 千寿制药株式会社 含有2－氨基－3－(4－溴苯甲酰基)苯乙酸的水成液制剂
AU2004305535A1 (en) 2003-12-09 2005-07-07 Alcon, Inc. Use of organic buffering agents to enhance the antimicrobial activity of pharmaceutical compositions
ES2561034T3 (es) 2003-12-09 2016-02-24 Novartis Ag Uso de bis-aminas para incrementar la actividad antimicrobiana de composiciones acuosas
EP1696878A1 (en) 2003-12-11 2006-09-06 Alcon, Inc. Ophthalmic compositions containing a polysaccharide/borate gelling system
US20050214382A1 (en) 2004-03-29 2005-09-29 Erning Xia Zinc preservative composition and method of use
CN101035526A (zh) * 2004-10-13 2007-09-12 默克公司 用于治疗高眼压的眼用组合物
US20060229219A1 (en) * 2005-04-11 2006-10-12 Advanced Medical Optics, Inc. Borate-polyol mixtures as a buffering system
US20070212420A1 (en) 2006-03-10 2007-09-13 Bausch & Lomb Incorporated Pharmaceutical formulations comprising polyanionic materials and zinc-based preservatives
US20070297990A1 (en) 2006-06-27 2007-12-27 Shah Mandar V Self-preserving composition
WO2008002118A1 (es) 2006-06-27 2008-01-03 Arturo Jimenez Bayardo Una formulación oftálmica en suspensión de etabonato de loteprednol y clorhidrato de ciprofloxacina
CN101516332B (zh) * 2006-09-21 2012-12-19 爱尔康研究有限公司 自身防腐的水性药物组合物
TWI394564B (zh) 2006-09-21 2013-05-01 Alcon Res Ltd 自行保存型水性藥學組成物
US8388941B2 (en) 2006-09-28 2013-03-05 Alcon Research, Ltd. Self preserved aqueous pharmaceutical compositions
US20080095863A1 (en) 2006-10-24 2008-04-24 Alcon Manufacturing Ltd. 2-pyrrolidone derivatives for preservation of ophthalmic, otic and nasal compositions
WO2008052037A2 (en) 2006-10-24 2008-05-02 Alcon Research, Ltd. Packaging materials for formulations containing 2-pyrrolidone derivatives
US7705112B2 (en) 2007-04-17 2010-04-27 Abbott Medical Optics Inc. Polyquaternium-1 synthesis methods
KR101541303B1 (ko) 2008-03-17 2015-08-03 알콘 리서치, 리미티드 보레이트-폴리올 복합체를 함유하는 수성 약학적 조성물
TWI544927B (zh) * 2008-03-17 2016-08-11 愛爾康研究有限公司 具有低濃度的表面活性劑以促進治療劑之生物可利用性的藥學組成物
US7999064B2 (en) 2009-04-23 2011-08-16 Abbott Medical Optics Inc. Polyquaternium-1 synthesis methods and associated formulations
TWI489997B (zh) * 2009-06-19 2015-07-01 Alcon Res Ltd 含有硼酸－多元醇錯合物之水性藥學組成物

Also Published As

Publication number Publication date
HUE030435T2 (en) 2017-05-29
US9421265B2 (en) 2016-08-23
RU2012101782A (ru) 2013-07-27
PT2722035T (pt) 2016-08-02
ES2803648T3 (es) 2021-01-28
TW201100103A (en) 2011-01-01
US20100324031A1 (en) 2010-12-23
PT3045164T (pt) 2020-07-14
AU2010262898B2 (en) 2015-02-12
BRPI1015996B8 (pt) 2021-05-25
CN102802604B (zh) 2016-02-10
ES2461617T3 (es) 2014-05-20
KR101738502B1 (ko) 2017-05-22
RU2563125C2 (ru) 2015-09-20
EP2722035B1 (en) 2016-04-27
EP2442790A1 (en) 2012-04-25
EP3437634A1 (en) 2019-02-06
CL2010000634A1 (es) 2011-03-11
PL3045164T3 (pl) 2020-10-19
BRPI1015996A2 (pt) 2016-04-26
JP2012530712A (ja) 2012-12-06
CY1123120T1 (el) 2021-10-29
US20160324967A1 (en) 2016-11-10
CY1117835T1 (el) 2017-05-17
PL2442790T3 (pl) 2014-08-29
DK3045164T3 (da) 2020-07-13
BRPI1015996A8 (pt) 2018-01-09
PL2722035T3 (pl) 2016-11-30
HRP20200979T1 (hr) 2020-10-16
SI3045164T1 (sl) 2020-08-31
AU2010262898A1 (en) 2011-12-15
JP2016183198A (ja) 2016-10-20
HUE049477T2 (hu) 2020-09-28
EP2722035A1 (en) 2014-04-23
AR077126A1 (es) 2011-08-03
DK2722035T3 (en) 2016-08-01
JP2014198729A (ja) 2014-10-23
KR20120028390A (ko) 2012-03-22
BRPI1015996B1 (pt) 2020-08-11
CA2763778A1 (en) 2010-12-23
EP3045164B1 (en) 2020-04-15
MX2011013107A (es) 2012-01-20
SMT201600249B (it) 2016-08-31
EP3045164A1 (en) 2016-07-20
ZA201108384B (en) 2013-01-30
AR122017A2 (es) 2022-08-03
CN104707145A (zh) 2015-06-17
WO2010148190A1 (en) 2010-12-23
CN102802604A (zh) 2012-11-28
SI2722035T1 (sl) 2016-09-30
US20150224196A1 (en) 2015-08-13
LT3045164T (lt) 2020-07-27
EP2442790B1 (en) 2014-03-26
PT2442790E (pt) 2014-05-12
CA2763778C (en) 2016-02-02
TWI489997B (zh) 2015-07-01
JP6017956B2 (ja) 2016-11-02
ES2584858T3 (es) 2016-09-29
HK1163521A1 (en) 2012-09-14
US9044484B2 (en) 2015-06-02
HRP20160953T1 (hr) 2016-10-07
SI2442790T1 (sl) 2014-05-30
DK2442790T3 (da) 2014-04-14
HK1194007A1 (en) 2014-10-10

Similar Documents

Publication Publication Date Title
UY32709A (es) Composiciones farmacéuticas acuosas que contienen complejos borato-poliol
UY31718A1 (es) Composiciones farmacéuticas acuosas que contienen complejos de borato y poliol
SV2010003706A (es) 2,6-diamino-pirimidin-5-il-carboxamidas como inhibidores de syk o jak quinasas
UY30605A1 (es) Composiciones farmacéuticas acuosas autoconservadas
BR112014032734A2 (pt) derivados de pirrolidina e seu uso como moduladores da série de reação de complemento
UY33201A (es) Compuestos de pirazol como antagonistas de crth2.
EA201590053A1 (ru) Модуляторы пути системы комплемента и их применение
CU20150163A7 (es) DERIVADOS DE 5-HETEROARIL-4-FENIL-4,5-DIHIDROPIRROLO(3,4-c)PIRAZOL-6-ONA ACTIVOS COMO INHIBIDORES DE BET
BR112015019720A2 (pt) inibidores de (benzil-ciano-metil)-amidas de ácido 2-aza-biciclo[2.2.1]heptano-3-carboxílico substituído da catepsina c
BR112014025711A2 (pt) composto, medicamento, e, uso de um composto
BRPI0916286B8 (pt) amidofenóxi-indazóis úteis como inibidores de c-met, seus usos, e composição farmacêutica
UY34359A (es) ?tratamiento de esclerosis múltiple con combinación de laquinimod e interferón-beta?.
CL2012000976A1 (es) Composicion antitranspirante que comprende una base, un activo antiperspirante y por lo menos un antioxidante; y metodo para reducir o eliminar la coloracion amarilla en las prendas de vestir.
CO6400171A2 (es) Formulaciones de imiquimod de baja concentración de dosis y regímenes de dosis de corta duración para tratar queratosis actínica
CO6710926A2 (es) Compuestos de n-heteroarilo
BR112014025702A2 (pt) compostos de tiofeno fotodinâmicos a base de metal e seus usos
BR112014006248A2 (pt) compostos de triazolopiridina como inibidores de pde10a
CR20110190A (es) Agente rodenticida sinérgico
BR112014002025A2 (pt) partículas que compreendem compostos ativos com base em poliacrilato
AR090930A1 (es) Composiciones oftalmicas con proteccion mejorada contra la desecacion y retencion
BR112012013252A2 (pt) composição farmacêutica tópica, preservativo, composto, e, uso do mesmo
CO7131368A2 (es) (r)-nifuratel, su uso para el tratamiento de infecciones y síntesis de (r) y (s)-nifuratel
GB2523707A (en) Novel pharmaceutical formulations and their use in the treatment of periodontal disease
BR112014005434A2 (pt) composições farmacêuticas
BR112015015250A2 (pt) derivados de pirrolidina, composições farmacêuticas e usos dos mesmos

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20190206